E
Tier
Long-acting IGF-1 analog for systemic anabolism.
Protein analogue of IGF-1
WADA Status:
Prohibited at all times (S2.3)
Human Trial Scoreboard
Completed human RCTs
None for this analogue
Largest Human Study
No human studies
Longest exposure
None studied
Most Recent Trial
No completed trial
Description
IGF-1 LR3 is a laboratory-modified version of insulin-like growth factor 1, altered in two ways: an extended chain at one end and a substitution that greatly reduces its binding to the proteins that normally carry IGF-1 in the blood. Because those binding proteins usually limit how much is active, reducing that binding makes it considerably more potent and longer lasting. It was created as a research reagent, largely for cell culture work. Recombinant human IGF-1 does exist as an approved medicine, mecasermin, for a rare growth disorder, and it is a different product from this one. No human trial of the LR3 analogue has been completed, and it is prohibited in tested sport.
What Are The Claims
Claims made for this compound: Muscle growth; Nutrient partitioning
Evidence
A long-acting IGF-1 analogue - a potent growth factor, not a mild peptide. The theoretical concern that matters is that IGF-1 signaling is implicated in tumor promotion, which is why sustained supraphysiologic elevation is not a casual intervention.
Evidence Strength
Animal/preclinical only
Caveats
Safety
Alternative Measures
Legal Status
US
Not approved
UK
Not approved
EU
Not approved
AU
Not approved
WADA
Prohibited at all times (S2.3)
Not approved. Research chemical. WADA-prohibited.
Citations
No completed peer-reviewed human clinical trial exists for this compound. Where a citation is absent below, that absence is the finding.